137 related articles for article (PubMed ID: 26083411)
1. Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib.
Klammer M; Dybowski JN; Hoffmann D; Schaab C
PLoS One; 2015; 10(6):e0128542. PubMed ID: 26083411
[TBL] [Abstract][Full Text] [Related]
2. Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Klammer M; Kaminski M; Zedler A; Oppermann F; Blencke S; Marx S; Müller S; Tebbe A; Godl K; Schaab C
Mol Cell Proteomics; 2012 Sep; 11(9):651-68. PubMed ID: 22617229
[TBL] [Abstract][Full Text] [Related]
3. Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Yang H; Sun B; Xu K; He Y; Zhang T; Hall SRR; Tan ST; Schmid RA; Peng RW; Hu G; Yao F
EBioMedicine; 2021 Jul; 69():103457. PubMed ID: 34224975
[TBL] [Abstract][Full Text] [Related]
4. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
5. Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations.
Sun Y; Zhang W; Chen Y; Ma Q; Wei J; Liu Q
Oncotarget; 2016 Feb; 7(8):9404-19. PubMed ID: 26824188
[TBL] [Abstract][Full Text] [Related]
6. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
7. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
Huang F; Reeves K; Han X; Fairchild C; Platero S; Wong TW; Lee F; Shaw P; Clark E
Cancer Res; 2007 Mar; 67(5):2226-38. PubMed ID: 17332353
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
12. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Kelley MJ; Jha G; Shoemaker D; Herndon JE; Gu L; Barry WT; Crawford J; Ready N
Cancer Invest; 2017 Jan; 35(1):32-35. PubMed ID: 27911119
[TBL] [Abstract][Full Text] [Related]
14. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
15. A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer.
Luo X; Liu Y; Wang R; Hu H; Zeng R; Chen H
J Proteomics; 2011 Apr; 74(4):528-38. PubMed ID: 21262398
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
17. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Lohmann S; Herold A; Bergauer T; Belousov A; Betzl G; Demario M; Dietrich M; Luistro L; Poignée-Heger M; Schostack K; Simcox M; Walch H; Yin X; Zhong H; Weisser M
Methods; 2013 Jan; 59(1):10-9. PubMed ID: 22796720
[TBL] [Abstract][Full Text] [Related]
19. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
20. Identification of gene signatures from RNA-seq data using Pareto-optimal cluster algorithm.
Mallik S; Zhao Z
BMC Syst Biol; 2018 Dec; 12(Suppl 8):126. PubMed ID: 30577846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
